Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
AIDS/HIV
100%
Rhesus Macaque
100%
Recombinant Vesicular Stomatitis Virus
100%
Intrarectal
62%
Heterologous Regimen
50%
Simian HIV
50%
Virus Vector Vaccine
50%
Immunogenicity
50%
Vaccine Candidate
50%
Vesicular Stomatitis Virus Vector
50%
Viremia
50%
Enhanced Resistance
50%
Virus Antigen
50%
HIV-infected Patients
50%
Ebola Glycoprotein
41%
Vesicular Stomatitis Virus
37%
Virus Envelope
29%
Memory T Cells
29%
Human Immunodeficiency Virus Infection
25%
Human Immunodeficiency Virus Vaccine
25%
Virus Vaccine
25%
Simian Immunodeficiency Virus
25%
Antibody Interactions
16%
Resistance to Infection
16%
CD154
16%
Correlates of Protection
16%
CD69
16%
Virus Pandemic
16%
Envelope Glycoprotein
16%
Nonhuman Primate
16%
IL-2 Production
16%
IFN Response
16%
Novel Recombinants
16%
At-risk Populations
16%
Genetic Immunization
16%
Vaccine Particles
12%
CD4 T Cells
12%
Cell-mediated Immune Response
12%
Vaccine Vector
12%
Transmembrane
12%
High Dose
12%
DNA Construct
12%
Envelope Protein
12%
Cytoplasmic Tail
12%
T Cell Activation
12%
Vaccine Delivery System
12%
Neutralizing Antibodies
12%
Tropism
12%
Non-associated
12%
Non-neutralizing Antibodies
12%
Immunology and Microbiology
Rhesus Monkey
100%
Vesiculovirus
100%
Human Immunodeficiency Virus
100%
Glycoprotein
66%
Immunogenicity
50%
Human Immunodeficiency Virus Antigen
50%
Viremia
50%
Viral Vector
50%
Infection
50%
Infectious Disease
50%
Ebola Virus
41%
Memory T Cell
33%
Viral Envelope
33%
CD69
25%
Upregulation
25%
CD154
25%
Population Risk
25%
Cladistics
25%
Interleukin 2
25%
HIV Vaccine
16%
Human Immunodeficiency Virus Infection
16%
Virus Vaccine
16%
Adoptive Immunity
8%
Drug Megadose
8%
Simian Immunodeficiency Virus
8%
T Cell Activation
8%
T-Helper Cell
8%
Neutralizing Antibody
8%
Antibody Response
8%
In Vitro
8%
Replication
8%
Antigen
8%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
50%
Viremia
50%
Immunogenicity
50%
Vesiculovirus
50%
Rhesus Monkey
50%
Virus Glycoprotein
16%
Human Immunodeficiency Virus Infection
16%
Virus Vaccine
16%
Human Immunodeficiency Virus Vaccine
16%
Ebola Virus
16%
Virus Envelope Protein
16%
Antigen
8%
Simian Immunodeficiency Virus
8%
Neutralizing Antibody
8%